Provectus Announces Presentation of Initial Results from Phase 1B Trial of PV-10® in Combination with KEYTRUDA® for Treatment of Checkpoint-Refractory Advanced Melanoma at SMR 2019 Congress
November 21, 2019 10:19 ET
|
Provectus Biopharmaceuticals Inc.
First 10 checkpoint-refractory melanoma patients treatedEstablished safety profiles of PV-10 and KEYTRUDA were maintained20% ORR and 40% DCR (RECIST 1.1)Changes in immune system activation biomarkers...
Provectus Names Harold Schmitz, PhD to Company's Scientific Advisory Board
September 11, 2019 07:00 ET
|
Provectus Biopharmaceuticals Inc.
Dr. Schmitz, General Partner of The March Fund and former Chief Science Officer of Mars, Incorporated is Provectus’ inaugural Scientific Advisory Board member KNOXVILLE, TN, Sept. 11, 2019 (GLOBE...
PROVECTUS ANNOUNCES GRANT OF ORPHAN DRUG DESIGNATION IN U.S. TO PV-10 FOR TREATMENT OF OCULAR MELANOMA
February 12, 2019 07:30 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that orphan drug designation (ODD) status was granted by the U.S. Food and Drug Administration (FDA) to small...